|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn835665073 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
120412s2012 nyua ob 001 0 eng |
| 010 |
|
|
|a 2020677601
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|e pn
|c DLC
|d YDXCP
|d EBLCP
|d AGLDB
|d VTS
|d AU@
|d STF
|d M8D
|d N$T
|d E7B
|d OCLCF
|d VLY
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 846980808
|a 964276424
|a 1162045932
|
| 020 |
|
|
|a 9781620818541
|q (ebook)
|
| 020 |
|
|
|a 162081854X
|
| 020 |
|
|
|z 9781620818466
|q (hardcover)
|
| 029 |
1 |
|
|a AU@
|b 000056864634
|
| 029 |
1 |
|
|a DEBBG
|b BV041049725
|
| 029 |
1 |
|
|a DEBBG
|b BV043775660
|
| 029 |
1 |
|
|a DEBSZ
|b 472781464
|
| 029 |
1 |
|
|a NZ1
|b 15023340
|
| 035 |
|
|
|a (OCoLC)835665073
|z (OCoLC)846980808
|z (OCoLC)964276424
|z (OCoLC)1162045932
|
| 050 |
|
4 |
|a RC848.H44
|b H47 2012eb
|
| 072 |
|
7 |
|a MED
|x 114000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.3623
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Hepatitis B :
|b new research /
|c Jeffrey T. Cox and Dedrick I. Owen.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical/Nova Science Publishers, Inc.,
|c [2012]
|
| 300 |
|
|
|a 1 online resource :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Virology research progress
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a HEPATITIS B: NEW RESEARCH; HEPATITIS B: NEW RESEARCH; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter I: Chemo -- and Immunotherapeutic Approaches for the Treatment of Hepatitis B Virus Infection; Abstract; Introduction; The Hepatitis B Virus; Life Cycle of Hepatitis B Virus; Therapeutic Approaches in Chronic Hepatitis B (CHB) Virus Infection; Current Chemotherapeutic Agents; Lamivudine (3-TC); Hepsera (Adefovir Dipivoxil, ADV); Tenofovir Disoproxil Fumarate (TDF); Telbivudine; Entecavir (Baraclude); Oxymatrine; Chemotherapeutic Agents in Pipeline; Clevudine.
|
| 505 |
8 |
|
|a ElvucitabineEmtricitabine; FLG; Amdoxovir; LB80380; Pradefovir; Other Nucleosides under Investigation; Acyclic Pyrimidine Nucleosides; Non-Nucleoside Agents in Pipeline; Bay 41-4109; n- (n-Nonyl)- Deoxygalactonojirimycin; MCC -- 478; Phenylpropenamide Derivatives AT- 61 and AT- 130; Current Immunotherapeutic Agents; Interferon-Ü (IFN-a); Pegylated interferon (PEG-IFN); Immunoglobulins ; Immunotherapeutic Agents in Pipeline; Immunomodulators; REP 9AC; Zadaxin (Thymosin-a); GS-9620; Therapeutic Vaccines; DV-601; Miscellaneous; NOV-205 (BAM-205); Myrcludex B; CYT107 or Interleukin 7 (IL-7)
|
| 505 |
8 |
|
|a Dendritic Cells (DC) Based TherapyCombination Therapy; 1. Combination of Chemotherapeutic Agents; Lamivudine Plus Adefovir Dipivoxil; Lamivudine Plus Telbivudine; Adefovir Dipivoxil Plus Emtricitabine; Tenofovir Disoproxil Plus Emtricitabine; Tenofovir Disoproxil Plus Entecavir; Adefovir Plus Entecavir; 2. Combination of Chemotherapeutic and Immunotherapeutic Agent(s); Lamivudine Plus Interferon; Lamivudine Plus Peginterferon; Hepatitis B e Antigen-Positive Chronic Hepatitis; Hepatitis B e Antigen-Negative Chronic Hepatitis; Telbivudine Plus Peginterferon; Adefovir Plus Peginterferon.
|
| 505 |
8 |
|
|a Interleukin-12 (IL-12) Plus LamivudineConventional IFN Plus Ribavirin; PEG- IFN Plus Ribavirin; Thymosin Plus Lamivudine (Plus IFN); 3. Combination Therapy Using Two Immunomodulators; Thymosin-Ü1 Plus IFN; Vaccine Plus IFNs; Conclusion; References; Chapter II: Hepatitis B and Dialysis; Abstract; Introduction; Epidemiology; HBV Transmission within Dialysis Units; Hepatitis B Serologic Markers; Hepatitis B Surface Antigen and Antibody; Hepatitis B Core Antigen and Antibody; Isolated Anti-HBc ; Hepatitis B E Antigen and Antibody; Hepatitis B Vaccination; The Hepatitis B Vaccine.
|
| 505 |
8 |
|
|a Efficacy of Hepatitis B VaccineStrategies for Improving Immune Response; Treatment of Hepatitis B in Dialysis Patients; Interferon-Alfa; Nucleoside or Nucleotide Analogues; Conclusion; References; Chapter III: Novel Carrier(s) Based Vaccine Design against Hepatitis B: Recent Updates; Abstract; 1. Introduction; 2. Hepatitis B Virus and Vaccination: An Insight; 3. Mucosal Immunization Against Hepatitis B; 3.1. Oral Immunization; 3.2. Nasal Immunization; 3.3. Topical Immunization; 4. Novel Carrier Based Hepatitis B Vaccine; 4.1. Liposomes; 4.2. PLGA Micro/Nano-particles.
|
| 546 |
|
|
|a English.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Hepatitis B
|x Research.
|
| 650 |
|
6 |
|a Hépatite B
|x Recherche.
|
| 650 |
|
7 |
|a MEDICAL
|x Hepatology.
|2 bisacsh
|
| 650 |
|
7 |
|a Hepatitis B
|2 fast
|
| 776 |
0 |
8 |
|i Print version:
|t Hepatitis B.
|d Hauppauge, NY : Nova Science Publishers, Inc., 2012
|z 9781620818466
|w (DLC) 2012937528
|
| 830 |
|
0 |
|a Virology research progress series.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541396
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3021919
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10686242
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 541396
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 10305888
|
| 994 |
|
|
|a 92
|b IZTAP
|
